Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.625    -0.025 (-3.85%)
Bid:
0.60
Ask:
0.65
Spread: 0.05 (8.333%)
Market Cap: £2.83m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Director's Notification

24 Dec 2010 09:06

RNS Number : 5892Y
Physiomics PLC
24 December 2010
 



Physiomics plc

 

(the "Company")

 

Director's Notification

 

In accordance with AIM Rule 17, the following information relating to Mark Chadwick, Chief Executive Officer of the Company, is required to be disclosed under

sub-paragraphs (iii) to (viii) of paragraph (g) of Schedule Two to the AIM Rules for Companies:

 

Mark Chadwick is also a director of EnviroGene Limited ("EnviroGene") which, on 23rd December 2010, appointed Roger G. Hale and Robert N. Lewis of PriceWaterhouseCoopers LLP ("PWC") as administrators. EnviroGene, which specialises in providing molecular diagnosis solutions to the water and oil and gas industries, had struggled with trading in the current financial climate. Following a substantial restructuring to save costs and a failed attempt at raising funds to continue operations, the decision was taken, in discussions with EnviroGene's major creditor, to put the company into administration. At the last balance sheet date of 20 December 2010 (taken from unaudited management accounts) the Net Asset Value of EnviroGene was approximately £316,378, excluding £790,000 of convertible loan notes. The majority of the loan notes were held by a single major investor.

 

Mark had, at all times, ensured Physiomics was fully aware of the working capital position of EnviroGene and the challenges EnviroGene was facing in the current climate.

 

Enquiries:

 

Physiomics plc

Dr Paul Harper, Non-Executive Chairman 

+44 (0)1865 784980

 

WH Ireland Limited

Katy Mitchell

+44 (0) 161 832 2174

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDNGMMZZLDKGGZG
Date   Source Headline
28th May 20267:00 amRNS-RHantavirus Translational Modelling Capability
27th May 20267:00 amRNSPhysiomics Awarded Multiple Contract Awards
26th May 20263:48 pmRNSHolding(s) in Company
21st May 20265:21 pmRNSHolding(s) in Company
15th May 20267:00 amRNSUpdate regarding CEO - Peter Sargent
12th May 20267:00 amRNSAppointment of Stewart Williams as Consultant
8th May 20267:00 amRNSStrategy Update
29th Apr 20266:15 pmRNSReplacement Result of Meeting and Board Changes
29th Apr 202611:00 amRNSResults of General Meeting and Board Changes
24th Apr 202610:30 amRNSReminder to Vote Against Resolutions
22nd Apr 20267:00 amRNSLaunch of Website for Requisitioned Meeting
17th Apr 20267:00 amRNSISS Voting Recommendation
14th Apr 20267:00 amRNSPhysiomics Awarded New Contract by Numab
8th Apr 20267:00 amRNSRequestioned GM and Investor Presentation
20th Mar 20269:45 amRNSHolding(s) in Company
20th Mar 20267:00 amRNSCancellation of General Meeting
18th Mar 20262:55 pmRNSResult of WRAP Retail Offer
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £110,000.00
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £110,000.00
17th Mar 20267:00 amRNSCompletion of Placing and WRAP Retail Offer Launch
17th Mar 20267:00 amRNSCompletion of Placing and WRAP Retail Offer Launch
16th Mar 20267:00 amRNSGeneral Meeting Request
16th Mar 20267:00 amRNSGeneral Meeting Request
13th Mar 20267:00 amRNSResult of WRAP Retail Offer
13th Mar 20267:00 amRNSResult of WRAP Retail Offer
11th Mar 20268:00 amRNSHolding(s) in Company
10th Mar 20267:01 amRNSWRAP Retail Offer for up to £49,999.98
16th Feb 20268:37 amRNSInterim Results
13th Feb 20262:23 pmRNSHolding(s) in Company
12th Feb 20267:00 amRNS-RPhysiomics Awarded New Contract
2nd Feb 202611:40 amRNSHolding(s) in Company
28th Jan 20267:00 amRNSPhysiomics Awarded New Contract by Numab
23rd Dec 20257:00 amRNSOptions Award
23rd Dec 20257:00 amRNSOptions Award
15th Dec 20257:00 amRNSPhysiomics Awarded Follow On Contract by UK Client
11th Dec 20257:00 amRNSPhysiomics Awarded New Contract by Numab
10th Dec 20257:00 amRNS-RPhysiomics Awarded New Contract by GARDP
8th Dec 20254:31 pmRNSHolding(s) in Company
4th Dec 20257:00 amRNS-RPhysiomics Awarded Two New Contracts
3rd Dec 20257:00 amRNSBoard Changes
18th Nov 20253:43 pmRNSResult of AGM
17th Oct 20257:00 amRNSNotice of AGM
30th Sep 20257:00 amRNSChange of Registered Office
29th Sep 20257:00 amRNSAnnual Financial Report
22nd Sep 20257:00 amRNSNotice of Results and Investor Presentation
6th Aug 20257:00 amRNSFollow-on Contract with UK Biotech Client
16th Jul 20257:00 amRNSContract Award
14th Jul 20257:00 amRNSTrading Update
10th Jul 20257:00 amRNSPlatform Implementation and Partnership Expansion
1st Jul 20257:00 amRNSContract Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.